Open AccessA subcutaneous abscess following anti‐programmed cell death 1/programmed death‐ligand 1 antibody treatment for lung cancer
Author(s) -
Sugino Hitomi,
Sawada Yu,
Nakamura Motonobu
Publication year - 2022
Publication title -
journal of cutaneous immunology and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.127
H-Index - 1
ISSN - 2574-4593
DOI - 10.1002/cia2.12219
Subject(s) - atezolizumab , medicine , lung cancer , programmed cell death , immune system , programmed cell death 1 , immunotherapy , cancer , antibody , immunology , pembrolizumab , cancer research , oncology , pd l1 , apoptosis , biology , biochemistry
Immune checkpoint inhibitor targeted programmed cell death 1/programmed death‐ligand 1 or CTLA4 develops immune cell‐mediated anti‐cancer treatment showing a beneficial impact on the clinical outcomes. On the other hand, these treatments sometimes enhance an undesirable immunological adverse reaction to various organs. Herein, we experienced a case of subcutaneous abscess located in the previously received appendectomy following atezolizumab for lung cancer.